Application of an expert system in the management of HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 15, Issue 5, 1997, Pages 356-362

  Pazzani, Michael J ^a   See, Darryl ^a   Schroeder, Edison ^a   Tilles, Jeremiah ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; Antiretrovirals; Cloning; Expert program; PCR; Sequencing

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; COMPUTER PROGRAM; EXPERT SYSTEM; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; PRIORITY JOURNAL;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0030723424     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199708150-00005     Document Type: Article

References (51)

1. DeClercq E. Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev 1995;8:200-39.
2. Frost S, McLean A. Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection. AIDS 1994;8:323-32.
3. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. JAMA 1996;276:118-25.
4. Holodniy M, Katzenstein D, Winters M, et al. Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy. J Acquir Immune Defic Syndr 1993;6:366-9.
5. Kahn J, Lagakos S, Richman D, et al. A controlled trial comparing zidovudine with didanosine in human immunodeficiency virus infection: The NIAID AIDS Clinical Trials Group. N Engl J Med 1992;327:581-7.
6. Schooley RT, Ramirez-Ronda C, Lange JM, et al. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy: Wellcome Resistance Study Collaborative Group. J Infect Dis 1996;173:1354-66.
7. Zhu QY, Scarborough A, Polsky B, Chou TC. Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains. AIDS Res Hum Retroviruses 1996;12:507-17.
8. Lange JM. Triple combinations: Present and future. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10(suppl 1):S77-82.
9. Nielsen C, Bruun L, Mathiesen L, Pedersen C, Gerstoft J. Development of resistance to zidovudine (ZDV) and didanosine (ddl) in HIV from patients in ZDV, ddl and alternating ZDV/ddl therapy. AIDS 1996;10:625-33.
10. Larder B, Kellam P, Kemp S. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 1991;5:137-44.
11. Larder B, Kemp S. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989;246:1155-8.
12. Frenkel L, Wagner M, Atwood S, Cummins T, Dewhurst S. Specific, sensitive, and rapid assay for HIV pol mutations associated with resistance to zidovudine and didanosine. J Infect Dis 1995; 33:342-7.
13. Jackson P. Introduction to expert systems. Reading, MA: AddisonWesley, 1990.
14. Pazzani M, Kibler D. The utility of knowledge in inductive learning. Machine Learning 1992;9:57-94.
15. Kellam P, Boucher C, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992;89:1934-8.
16. Fontenant G, Johnston K, Cohen J, Gallaher W, Robinson J, Luftig R. PCR amplification of HIV-1 proteinase sequences directly from lab isolates allows determination of five conserved domains. Virol 1992;190:1-10.
17. Gu Z, Gao Q, Fang H, et al. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1994;38:275-81.
18. Clark J. Novel non-templated nucleotide addition reactions catalyzed by procaryotic and eucaryotic DNA polymerases. Nucleic Acid Res 1988;20:9677-86.
19. Giesecke H, Obermaier B, Domdey H. Rapid sequencing of the Sendai virus 6.8 kb large (L) gene through primer walking with an automated DNA sequencer. J Virol Methods 1992;38:47-60.
20. St Clair M, Martin J, Tudor W. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991;253:1557-9.
21. Gu Z, Gao Q, Li X, Parniak M, Wainberg M. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J Virol 1992;66:7128-35.
22. Gu Z, Gao Q, Fang H, Parniak M, Brenner B, Wainberg M. Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene. Leukemia 1994; 851:5166-9.
23. Richman D, Shin C, Lowy I, Rose J, Prodanovich P, Goff S, Griffin J. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Accid Sci USA 1991;88:11241-5.
24. El-Farrash M, Kuroda M, Kitazaki T, Masuda T, Kato K, Hatanaka M, Harada S, Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor. J Virol 1994;68:233-9.
25. Dueweke T, Pushkarskaya T, Poppe S, et al. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other non-nucleoside inhibitors. Proc Natl Acad Sci USA 1993;90: 4713-7.
26. Hammer S, Kessler H, Saag M. Issues in combination antiretroviral therapy: a review. J Acquir Immune Defic Syndr 1994;7 Suppl 2:524-35.
27. Holodniy M, Mole L, Margolis D, et al. Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudinedidanosine combination therapy. J Virol 1995;69:3510-6.
28. Michael N, Davis KE, Loomis-Price L, VanCott T, Burke D, Redfield R, Birx D. V3 seroreactivity and sequence variation: Tracking the emergence of V3 genotypic variation in HIV-1-infected patients. AIDS 1996;10:121-9.
29. Luehrsen KR, Marr L, van der Knaap E, Cumberledge S. Analysis of differential display RT-PCR products using fluorescent primers and GENESCAN software. Biotechniques 1997;22:168-74.
30. Ohno-Machado L, Parra E, Henry S, Tu S, Musen M. AIDS 2: A decision-support tool for decreasing physician's uncertainty regarding patient eligibility for HIV treatment protocols. Proceedings of the 17th Annual Symposium on Computer Applications in Medical Care, Washington, DC, 1993:429-33.
31. Boucher C, O'Sullivan E, Mulder A, et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive patients. J Infect Dis 1992; 165: 105-10.
32. Gurusinghe A, Land S, Birch C, et al. Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS. J Med Virol 1995;46:238-43.
33. Caliendo A, Savara A, An D, DeVore K, Kaplan J, D'Aquila R. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication, J Virol 1996;70:2146-53.
34. Quan Y, Gu Z, Li X, Li Z, Morrow C, Wainberg M. Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2′-dideoxy-3′-thiacytidine by mutated M184V human immunodeficiency virus type 1. J Virol 1996;70:5642-5.
35. Iversen AK, Shafer RW, Wearly K, Winters MA, Mullins JI, Chesebro B, Morgan TC. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 1996;70:1086-90.
36. Hooker D, Tachedjian G, Soloman A, et al. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3′-azido-3′-deoxythymidine. J Virol 1996;70:8010-8.
37. Kew Y, Saloman H, Olsen L, Wainberg M, Prasad V. The nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptse displays a broader cross-resistance that extends to nonnucleoside inhibitors. Antimicrob Agents Chemother 1996;40:1711-4.
38. Zhu Q, Scarborough A, Polsky B, Chou T. Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains. AIDS Res Hum Retroviruses 1996;12:507-17.
39. Richman D, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994;68:1660-6.
40. Richman DD. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 1993;37:1207-13.
41. Richman D, Shih CK, Lowy I, Rose J, Prodanovich P, Goff S, Griffin J. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 1991;88:11241-5.
42. Havlir, Eastman S, Gamst A, Richman D. Nevirapine-resistant human immnodeficiency virus: Kinetics of replication and estimated prevalence in untreated patients. J Virol 1996;70:7894-9.
43. Dueweke TJ, Pushkarskaya T, Poppe SM, et al. A mutation in reverse transcriptase of bis(heteroaryl) piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other non-nucleoside inhibitors. Proc Natl Acad Sci USA 1993;90: 4713-7.
44. Ho DD, Toyoshima T, Mo H, et al. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetic protease inhibitor. J Virol 1994;68:2016-2020.
45. Kaplan AH, Michael SF, Wehbie RS, et al. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of viral protease. Proc Natl Acad Sci USA 1994;91:5597-601.
46. Boucher C. Rational approaches to resistance using saquinavir. AIDS 1996;10(suppl 1):S15-9.
47. Schmidt J, Ruiz L, Clotet B, et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996;10:995-9.
48. Condra J, Holder D, Schlief W, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996;70:8270-6.
49. Patick A, Duran M, Cao Y, et al. Genotypic analysis of HIV-1 variants isolated from patients treated with the protease inhibitor Nelfinavir, alone or in combination with d4T or AZT and 3TC [Abstract]. Presented at the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1997.
50. Jacobsen H, Haenggi M, Ott M, Duncan I, Andreoni M, Vella S, Mous J. Reduced sensitivity to saquinavir: An update on genotyping from phase I/II trials. Antiviral Res 1996;29:95-7.
51. Taburet A, Singlas E. Drug interactions with antiviral drugs. Clin Pharmacokinet 1996;30:385-401.